Kyverna Therapeutics (KYTX) Current Assets (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Current Assets came in at $241.7 million in Q1 2026, down 2.39% YoY from $247.7 million in Q1 2025, and down 14.57% on a QoQ basis from $283.0 million in Q4 2025.
Kyverna Therapeutics (KYTX) Current Assets (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Current Assets data on file, last reported at $241.7 million in Q1 2026.
- Quarterly Current Assets fell 2.39% year-over-year to $241.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $241.7 million (down 2.39% YoY) and the FY2025 annual result came in at $283.0 million, down 2.63% from the prior year.
- Current Assets eased to $241.7 million in Q1 2026, from $283.0 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $375.5 million in Q1 2024 to a low of $60.7 million in Q4 2023.
- A 4-year average of $256.3 million and a median of $265.3 million in 2025 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets jumped 379.03% — and 2025, when it tumbled 46.24%.
- Tracing KYTX's Current Assets over 4 years: stood at $60.7 million in 2023, then surged by 379.03% to $290.6 million in 2024, then dropped by 2.63% to $283.0 million in 2025, then slipped by 14.57% to $241.7 million in 2026.
- The last three Current Assets figures came in at $241.7 million (Q1 2026), $283.0 million (Q4 2025), and $174.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | 206.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 206.54 Mn |
| Mar 31, 2026 | 241.73 Mn |
| Dec 31, 2025 | 282.95 Mn |
| Sep 30, 2025 | 174.93 Mn |
| Jun 30, 2025 | 214.33 Mn |
| Mar 31, 2025 | 247.65 Mn |
| Dec 31, 2024 | 290.60 Mn |
| Sep 30, 2024 | 325.37 Mn |
| Jun 30, 2024 | 348.82 Mn |
| Mar 31, 2024 | 375.49 Mn |
| Dec 31, 2023 | 60.66 Mn |